ID   CMK-86
AC   CVCL_2804
SY   CMK86
DR   BTO; BTO:0004960
DR   cancercelllines; CVCL_2804
DR   Cell_Model_Passport; SIDM01940
DR   Cosmic; 2089670
DR   DepMap; ACH-001037
DR   GEO; GSM888004
DR   JCRB; IFO50428
DR   PharmacoDB; CMK86_212_2019
DR   Progenetix; CVCL_2804
DR   Wikidata; Q54813774
RX   PubMed=16778363;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (PubMed=16778363).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0.34%; East Asian, North=91.48%; East Asian, South=8.18%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 9,11
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 18
DI   NCIt; C2993; Down syndrome
DI   NCIt; C43223; Myeloid leukemia associated with Down syndrome
DI   ORDO; Orphanet_870; Down syndrome
DI   ORDO; Orphanet_99887; Acute megakaryoblastic leukemia in Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0216 ! CMK
SX   Male
AG   10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=16778363; DOI=10.1620/tjem.209.169;
RA   Kanezaki R., Toki T., Xu G., Narayanan R., Ito E.;
RT   "Cloning and characterization of the novel chimeric gene p53/FXR2 in
RT   the acute megakaryoblastic leukemia cell line CMK11-5.";
RL   Tohoku J. Exp. Med. 209:169-180(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//